MedTrace Logo

Metabolite Levels in Ovarian Cancer Patients Receiving Maintenance PARP Inhibitors

NCT04917744 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5

Last updated 2025-04-03

No results posted yet for this study

Summary

This study evaluates blood samples and compares levels of metabolites (levels of vitamins, carbohydrates, proteins, etc., that are in the blood), before and after the plasma exchange in patients scheduled to receive immunotherapy for their ovarian cancer. The information gained from this study may help researchers better understand the side effects from each treatment and possibly lessen those side effects for future treatments.

Conditions

  • Ovarian Carcinoma

Interventions

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

OTHER

Laboratory Biomarker Analysis

Ancillary studies

OTHER

Medical Chart Review

Review of medical charts

Sponsors & Collaborators

Principal Investigators

  • Jacob J. Orme, M.D., Ph.D. · Mayo Clinic in Rochester

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2023-04-17
Completion
2024-02-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04917744 on ClinicalTrials.gov